Home Consent Form Library Clinical ResearchClinical Trial Participation

Clinical Research Template Tool

Free Clinical Trial Participation Consent Form Template

Operational & Compliance DisclaimerDisclaimer: This template is a sample for operational and administrative purposes only. ConsentCollect is a software platform, not a law firm or a healthcare provider. Consult with qualified legal counsel and medical directors to ensure compliance with local regulations before deploying any clinical consent form.

Professional medical consent form template for Clinical Trial Participation

Informed Consent for Participation in an Interventional Clinical Trial

Patient Informed Consent Documentation

Study and Participant Information

Research Institution / Sponsor

Principal Investigator

Participant Full Legal Name

Date of Birth

Full Study Title

ClinicalTrials.gov Identifier (NCT Number)

IRB Protocol Number

Reviewing IRB / Ethics Committee

Clinical Trial Phase

IRB Approval Date

Participant Email Address

Participant Phone Number

Study Coordinator Contact Phone

Study Coordinator Contact Email

Voluntary Nature of Participation

Your participation in this research study is completely voluntary. You may choose not to participate, and if you agree to participate, you may withdraw your consent and stop participating at any time without penalty or loss of any benefits to which you are otherwise entitled. Your decision to participate or not will not affect your current or future medical care at this institution. Withdrawing from the study will not affect your legal rights. In the event of withdrawal, the study team may need to retain and analyze data already collected from you if required by the regulatory protocol or the IRB.

Purpose and Background of the Research

You are being invited to participate in a research study to evaluate [the safety and efficacy of an investigational drug/device/intervention as specified in the study protocol]. Research studies are conducted to generate evidence about whether new treatments, devices, or approaches are safe, effective, and better than existing options. Clinical trials progress through phases: Phase I studies primarily assess safety and dosing in small groups; Phase II studies evaluate preliminary efficacy and safety in larger groups; Phase III studies compare the new treatment to existing standard-of-care treatment in large, randomized, controlled populations; Phase IV studies monitor long-term safety after regulatory approval. You are invited to participate in a Phase [X] study, meaning [the study team should describe the specific context of this phase].

Randomization and Blinding

This study is a randomized controlled trial. If you agree to participate, you will be randomly assigned (like a coin toss) by a computer to one of the study arms: (1) the experimental treatment group, which receives the investigational drug/device; or (2) the control group, which receives [the current standard treatment / an active comparator / a placebo (inactive substance)]. You will have an approximately equal chance of being assigned to either group. This study [is / is not] double-blinded: [In a double-blind study, neither you nor the study team members know which treatment you are receiving until the study code is broken at the pre-specified analysis time. / You and/or the study team will know which treatment you are receiving.] Randomization and blinding are essential to ensure that the study results reflect the true effect of the treatment and are not influenced by expectation or bias.

Study Procedures and Time Commitment

Screening visit: medical history review, physical examination, laboratory tests, ECG, and imaging as specified in the protocol, to confirm eligibility criteria.

Investigational treatment administration: study drug or device delivered on the schedule specified in the protocol (e.g. daily oral tablet, weekly IV infusion, single-device implant).

Follow-up visits: scheduled clinic visits at defined intervals for safety assessments, blood and urine tests, questionnaires, and imaging scans as per the protocol visit schedule.

Patient diary: daily electronic or paper diary recording symptoms, medication use, and adverse events as instructed by the study team.

Total time commitment: estimated [X] hours over [Y] weeks/months of active participation plus [Z] months of long-term safety follow-up.

Foreseeable Risks and Discomforts

Risks of the investigational drug or device: [The study team must insert the specific known and potential risks based on preclinical data and Phase I/II experience as listed in the Investigator's Brochure and protocol, e.g.: nausea, fatigue, elevated liver enzymes, specific organ toxicities, known adverse drug reactions].

Risks of the study procedures: phlebotomy-related bruising, discomfort, or haematoma from frequent blood draws; low-dose radiation exposure from protocol-required CT scans; risks specific to any invasive procedure (biopsy, lumbar puncture) required by the protocol.

Potential unknown risks: because the investigational agent is new, there may be unforeseen risks not identified in preclinical or earlier-phase studies. New safety information identified during the study will be disclosed to all participants promptly.

Placebo risk: participants assigned to the control or placebo arm will not receive the investigational treatment during the blinded phase. If the investigational treatment proves effective, delayed access to it may be a disadvantage.

Reproductive risk: the investigational drug may be harmful to a developing fetus or infant. Women of childbearing potential must use two forms of highly effective contraception for the duration of the study and for [X] months following the last dose. Breastfeeding is not permitted during study participation.

Potential Benefits

There may be no direct medical benefit to you from participating in this study. The investigational treatment may or may not improve your condition; this is precisely what the study is designed to determine. The knowledge gained from this study may benefit future patients with this condition. The information collected about your health through study visits and tests may be of indirect benefit by enabling closer monitoring of your condition during the study period.

Reasonable Alternatives to Participation

Choose not to participate in this study. In this case, you will still receive standard clinical care for your condition under the direction of your physician.

Receive standard FDA-approved medical or surgical treatments currently available for your specific medical condition.

Participate in other ongoing clinical trials at this or other institutions, if you meet their eligibility criteria.

Palliative or supportive care focused on relieving symptoms and improving comfort, depending on your health status.

Confidentiality and Data Privacy (HIPAA Authorization)

Your participation in this study and your personal health information will be kept confidential to the extent permitted by law. Study records will be identified only by a participant code number. Your identifying information will be kept in a separate, locked file accessible only to the study team. The study sponsor, the IRB, and regulatory authorities (FDA, EMA) may inspect study records. A Certificate of Confidentiality from the [relevant federal agency] protects identifiable research information from compelled disclosure in civil, criminal, or administrative proceedings. Research data will be retained for a minimum of 15 years following study completion as required by federal regulations.

HIPAA Authorization for Research Use of Protected Health Information

By signing this consent form, you are also authorizing the study team to access, use, and disclose your Protected Health Information (PHI) as defined under HIPAA for the purposes of conducting this clinical trial. The information that may be used or disclosed includes: medical history, laboratory results, imaging reports, physical examination findings, and any other health data relevant to the study protocol. Authorized recipients of your PHI include: the study sponsor (and its agents), the IRB, regulatory agencies (FDA, EMA), and study monitoring bodies. You have the right to revoke this authorization at any time in writing; however, revocation will not affect uses already made during your participation. Your refusal to authorize use of your PHI will result in your ineligibility for this study.

Compensation and Study Costs Summary

Compensation: [Specify: e.g. no compensation / $X per completed visit / travel reimbursement up to $X]. All study-required procedures, laboratory tests, and investigational drugs provided as part of this trial will be at no cost to you. Standard-of-care procedures that would be performed regardless of study participation may be billed to your insurance. Any injury directly caused by study procedures will be treated at no cost to you. Compensation for study-related injuries beyond treatment costs is not available unless otherwise specified by the sponsor. If you believe you have been injured as a result of this research, contact [Study Injury Contact].

Right to Withdraw Without Penalty

Your participation in this clinical trial is entirely voluntary. You may withdraw at any time for any reason without penalty, loss of benefits to which you are otherwise entitled, or adverse effect on your relationship with the clinical team. Withdrawal from the study will not affect your access to standard medical care. If you withdraw, any data or samples collected before withdrawal may be retained and used in the study analysis unless you specifically request their destruction in writing.

Language Access and Interpreter Services

If English is not your primary language or if you have difficulty reading, a qualified interpreter is available to translate this document or read it aloud to you at no cost. The IRB-required short form process for non-English speakers will be followed if applicable. Please notify the study coordinator before signing this document.

Copy of Consent Acknowledgment

Federal regulations (21 CFR 50.27 and 45 CFR 46.117) require that you receive a signed copy of this informed consent document. I acknowledge that I have received a copy of this signed consent form for my own records.

Participant Authorization

I confirm that I have read or had read to me this consent form. All my questions have been answered to my satisfaction. I voluntarily agree to participate in this study. I understand I may withdraw at any time without penalty. I authorize the use and disclosure of my health information for the purposes of this study as described above.

Signatures and Verification

Participant / LAR Signature

Relationship (if LAR)

Principal Investigator / Delegated Researcher Signature

Witness Signature (if required by IRB)

Date and Time of Consent

Consent Form Version Date Used

Document ID: CC-CLINICAL-TRIAL-CONSENT-FORM

Need to print or customize this template?

Download a clean PDF copy or customize it in our Free Consent Builder. No account required.

Looking for a complete clinical workflow?

Standard PDF consent forms still leave your practice exposed to malpractice disputes. If you want verified patient comprehension quizzes, automated signing order tracking, biometric signature seals, and direct Epic/Cerner EHR FHIR R4 integration, then upgrade to our full ConsentCollect App.

Free Document Schema Specifications

Template Classification:Clinical Trial Participation Layout

Target File Format:Printable PDF / HTML Structure

Customization Capability:Fully Editable Text & Checklist Fields

Licensing & Rights:Free Personal & Practice-Wide Use

How to Use the Digital Clinical Trial Participation Consent Template

The Clinical Trial Participation document layout available on this page is a structured administrative schema designed for clinical research practice managers, compliance coordinators, and healthcare operations teams. IRB-compliant informed consent form for clinical trial enrolment covering study phases, randomization, participant rights, and regulatory disclosure requirements.

Using the ConsentCollect Free Builder, administrative staff can import this clinical trial participation schema and configure every field to match their specific facility requirements. The builder supports drag-and-drop field reordering, custom label editing, signature block layout control, and client-side PDF generation, with no coding knowledge required and no account needed.

Once the clinical trial participation layout is finalized, it can be printed as a high-resolution paper document, embedded into a digital patient intake kiosk, or exported as a structured JSON payload for integration into an existing EHR or practice management system. Organizations running the full ConsentCollect App subscription gain access to verified comprehension tracking, automated signing sequence management, biometric signature seals, and FHIR R4 interoperability with Epic and Cerner platforms.

❓ Frequently Asked Questions

How do I import and configure this Clinical Trial Participation document layout in the Free Builder?

Click the "Customize in Free Builder" button on this page. The form schema opens directly in the client-side ConsentCollect Free Builder canvas with all fields, sections, and signature blocks pre-loaded. You can then drag and drop additional fields, relabel any section header, swap placeholder text for your facility name and provider credentials, and rearrange the field order to match your clinic workflow, all without creating an account.

What document structure and field types does this Clinical Trial Participation layout include?

This layout contains 16 structured sections covering patient identification fields, administrative intake data, and signature capture blocks. Practice managers and compliance officers can override any field label or placeholder value inside the builder to match their own intake schema.

Can I use this Clinical Trial Participation template for my Clinical Research practice without a paid subscription?

Yes. The Free Advanced Form Builder is entirely public with no account required. You can open this clinical trial participation layout, edit all fields, and export a print-ready PDF or copy the underlying JSON schema at no cost. A paid ConsentCollect App subscription unlocks additional workflow features such as encrypted transmission, timestamped audit logs, multi-party signing order, and direct FHIR R4 EHR integrations.

Does this page provide clinical, legal, or medical advice about clinical trial participation procedures?

No. This page is an administrative document schema tool hosted by ConsentCollect, a B2B compliance software platform. The form layout is provided for operational and administrative configuration purposes only. ConsentCollect is not a law firm, healthcare provider, or clinical advisory service. Before deploying any consent document to patients, the finished form must be reviewed by your organization's qualified legal counsel and a licensed medical director to confirm compliance with applicable regulations in your jurisdiction.

How do I export, print, or integrate this Clinical Trial Participation form schema into my EHR system?

After editing in the Free Builder, use the Export button to download a high-resolution PDF suitable for physical signature collection. Alternatively, copy the JSON schema payload for use in your own patient intake database or web application. Subscribers to the full ConsentCollect App can push finalized templates directly into Epic or Cerner workflows via a certified FHIR R4 integration layer without any manual re-entry.

Consent Form Moat